The acquisition of Forte for $2.2B in cash brings a first-in-class anti-CD122 antibody, FB102, into the immunology portfolio, targeting high unmet needs in vitiligo and celiac disease. The deal, expected to close in Q3 2026, aligns with long-term growth and Vision 2030.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.